Opexa's share price tumbles as lead MS drug fails
This article was originally published in Scrip
Shares in the US biotech company Opexa Therapeutics lost 94% of their value after a Phase IIb study of its lead product Tovaxin failed. The firm's share price on Nasdaq closed at $0.22 on September 19th after the top-line data were released at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.